Sugi Predict

Sugi Predict / Compounds / SCHEMBL736261

SCHEMBL736261

SCHEMBL736261

O=C(Nc1ccccc1)c1ccnc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.62
▸ HTT P42858 1/20 0.60
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ KCNK3 O14649 3/20 0.54
▸ KCNK9 Q9NPC2 2/20 0.54
▸ CTNNB1 P35222 1/20 0.54
▸ TCF7L2 Q9NQB0 1/20 0.54
▸ SLC6A3 Q01959 1/20 0.53
▸ KCNH2 Q12809 1/20 0.53
▸ TAAR1 Q96RJ0 1/20 0.53
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC2 Q92769 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ KCNQ3 O43525 1/20 0.53
▸ KCNQ2 O43526 1/20 0.53
▸ BRAF P15056 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16703342 0.85 CYP11B1 (0.65) LMNANPC1RAB9AALDH1A1
SCHEMBL27961572 0.84 SLC6A3 (0.54) LMNANPC1RAB9AALDH1A1CTNNB1
SCHEMBL28821933 0.84 JAK2 (0.63) NPC1RAB9AKCNK3KCNK9KCNQ3
SCHEMBL259371 0.84 KMT2A (0.66) LMNAHTTNPC1RAB9AALDH1A1
SCHEMBL16430829 0.84 PTGS1 (0.54) ALDH1A1KCNK3KCNK9BRAFJAK2
SCHEMBL1517075 0.84 BRAF (0.53) KCNK3KCNK9KCNQ3KCNQ2BRAF
SCHEMBL24473977 0.83 TSHR (0.64) LMNANPC1RAB9AALDH1A1KDM4E
SCHEMBL30587153 0.83 TSHR (0.64) LMNANPC1RAB9AALDH1A1KDM4E
SCHEMBL2846498 0.82 HDAC4 (0.49) LMNAHTTNPC1RAB9AKDM4E
SCHEMBL11134265 0.82 LMNA (0.64) LMNAHTTNPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2025-05-29 — — US disclosed
US-12168016-B2 Aryl-OR heteroaryl-substituted benzene compounds Epizyme, Inc. (US) 2024-12-17 — — US disclosed
US-12168015-B2 Aryl-or heteroaryl-substituted benzene compounds Epizyme, Inc. (US) 2024-12-17 — — US disclosed
US-12161645-B2 Aryl-or heteroaryl-substituted benzene compounds Epizyme, Inc. (US) 2024-12-10 — — US disclosed
US-20240277723-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2024-08-22 — — US disclosed
US-20240245697-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2024-07-25 — — US disclosed
US-20240245698-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. 2024-07-25 — — US disclosed
US-20240165121-A1 SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2024-05-23 — — US disclosed
EP-4360712-A2 ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS Epizyme, Inc. (US) 2024-05-01 — — EP disclosed
EP-3943485-B1 ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS EPIZYME INC (US) 2023-12-27 — — EP disclosed
US-5827859-A ADMINISTERED TO TREAT AIDS; VIRICIDES AGOURON PHARMACEUTICALS, INC. 1998-10-27 — — US disclosed
US-5827891-A FOR TREATMENT OF AIDS, BLOCKING REPLICATION OF HIV VIRUS AGOURON PHARMACEUTICALS, INC. 1998-10-27 — — US disclosed
US-5824688-A HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 1998-10-20 — — US disclosed
EP-0741719-A4 INTERMEDIATE AND PROCESS FOR MAKING LILLY CO ELI (US) 1997-04-02 — — EP disclosed
EP-0741719-A1 INTERMEDIATE AND PROCESS FOR MAKING ELI LILLY AND COMPANY (US) 1996-11-13 — — EP disclosed
EP-0722439-A1 HIV PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1996-07-24 — — EP disclosed
US-5484926-A VIRICIDES AND ENZYME INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1996-01-16 — — US disclosed
US-5461154-A HIV protease inhibitors ELI LILLY AND COMPANY (US) 1995-10-24 — — US disclosed
WO-1995021164-A1 INTERMEDIATE AND PROCESS FOR MAKING ELI LILLY AND COMPANY (US) 1995-08-10 — — WO disclosed
WO-1995009843-A1 HIV PROTEASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1995-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12168016-B2 Aryl-OR heteroaryl-substituted benzene compounds AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885
US-20240245698-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885
US-20240277723-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885
US-12161645-B2 Aryl-or heteroaryl-substituted benzene compounds AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885
US-20250170138-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885
US-20240245697-A1 ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885
US-20240165121-A1 SUBSTITUTED BENZENE COMPOUNDS CYP1B1, TP53, VHL LMNA 1888/4885HTT 701/4885NPC1 1195/4885
US-12168015-B2 Aryl-or heteroaryl-substituted benzene compounds AHR, ARNT, CYP1B1 LMNA 2405/4885HTT 291/4885NPC1 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.